Published in Nat Rev Genet on September 15, 2016
Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast Cancer | NCT04999540
Histone Methylation by Temozolomide; A Classic DNA Methylating Anticancer Drug. Anticancer Res (2016) 0.75
Transcriptional Addiction in Cancer. Cell (2017) 0.75
Stemness in Cancer: Stem Cells, Cancer Stem Cells, and Their Microenvironment. Stem Cells Int (2017) 0.75
Epigenetic Regulation of Redox Signaling in Diabetic Retinopathy: Role of Nrf2. Free Radic Biol Med (2016) 0.75
Re-engineering the Pancreas Tumor Microenvironment: A "Regenerative Program" Hacked. Clin Cancer Res (2017) 0.75
Inhibition of DNA and Histone Methylation by 5-Aza-2'-Deoxycytidine (Decitabine) and 3-Deazaneplanocin-A on Antineoplastic Action and Gene Expression in Myeloid Leukemic Cells. Front Oncol (2017) 0.75
Contribution of Neuroepigenetics to Huntington's Disease. Front Hum Neurosci (2017) 0.75
Large-scale DNA methylation expression analysis across 12 solid cancers reveals hypermethylation in the calcium-signaling pathway. Oncotarget (2017) 0.75
Epigenetic regulation in cell senescence. J Mol Med (Berl) (2017) 0.75
Three-dimensional genome architecture and emerging technologies: looping in disease. Genome Med (2017) 0.75
The Short Isoform of BRD4 Promotes HIV-1 Latency by Engaging Repressive SWI/SNF Chromatin-Remodeling Complexes. Mol Cell (2017) 0.75
Development and clinical application of radiomics in lung cancer. Radiat Oncol (2017) 0.75
Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E). Blood (2017) 0.75
Cancer: Keeping it real to kill glioblastoma. Nature (2017) 0.75
Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer (2017) 0.75
Molecular Pathways: Metabolic control of histone methylation and gene expression in cancer. Clin Cancer Res (2017) 0.75
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
The epigenomics of cancer. Cell (2007) 30.91
Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet (2003) 25.57
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell (2004) 21.30
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Selective inhibition of BET bromodomains. Nature (2010) 18.79
Mutation in TET2 in myeloid cancers. N Engl J Med (2009) 16.07
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet (2012) 15.21
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol (2009) 12.41
Epigenetics in human disease and prospects for epigenetic therapy. Nature (2004) 11.46
A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer (2011) 11.33
The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 11.29
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell (2010) 11.20
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet (2010) 10.97
Integrative analysis of 111 reference human epigenomes. Nature (2015) 10.32
Cellular differentiation, cytidine analogs and DNA methylation. Cell (1980) 10.15
Methylation-induced repression--belts, braces, and chromatin. Cell (1999) 9.89
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet (1999) 9.53
Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature (2006) 9.20
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature (2012) 8.66
Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell (2006) 8.46
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood (2006) 8.38
Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell (2013) 8.37
Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet (1994) 8.34
IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (2012) 7.95
Cancer epigenetics: from mechanism to therapy. Cell (2012) 7.74
DNA methylation age of human tissues and cell types. Genome Biol (2013) 7.48
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature (2012) 7.01
Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nat Genet (2011) 5.70
A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet (2002) 5.38
Mechanisms of immune evasion by tumors. Adv Immunol (2006) 5.34
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science (2013) 5.10
Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 5.10
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell (2011) 4.90
Changes in DNA methylation patterns in subjects exposed to low-dose benzene. Cancer Res (2007) 4.89
5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science (1990) 4.80
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov (2011) 4.60
Chemical phylogenetics of histone deacetylases. Nat Chem Biol (2010) 4.36
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood (2003) 4.07
Genomic Classification of Cutaneous Melanoma. Cell (2015) 3.91
Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood (2002) 3.89
Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell (2012) 3.82
Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell (2012) 3.65
Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature (2015) 3.64
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol (2014) 3.62
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A (1998) 3.62
Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res (2006) 3.59
STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene (2001) 3.36
A chromatin localization screen reveals poly (ADP ribose)-regulated recruitment of the repressive polycomb and NuRD complexes to sites of DNA damage. Proc Natl Acad Sci U S A (2010) 3.31
Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. Cancer Cell (2007) 3.15
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov (2014) 3.09
Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer Cell (2011) 3.07
Mutant BRAF melanomas--dependence and resistance. Cancer Cell (2011) 2.87
Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res (1998) 2.83
Long-term haematopoietic reconstitution by Trp53-/-p16Ink4a-/-p19Arf-/- multipotent progenitors. Nature (2008) 2.82
Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature (2014) 2.81
Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells. Nature (2013) 2.76
DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. Cancer Res (2006) 2.69
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell (2015) 2.60
Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island. PLoS Genet (2008) 2.55
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell (2015) 2.52
Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell (2013) 2.50
DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. Cell (2015) 2.45
Targeting DNA methylation. Clin Cancer Res (2009) 2.45
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood (2014) 2.44
Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell (2014) 2.28
Regulation of DNA-damage responses and cell-cycle progression by the chromatin remodelling factor CHD4. EMBO J (2010) 2.25
Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape. Science (2016) 2.25
DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol (2009) 2.23
Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol (2000) 2.21
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol (2011) 2.20
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia (2011) 2.12
The NuRD chromatin-remodeling complex regulates signaling and repair of DNA damage. J Cell Biol (2010) 2.06
DNA methylation models histone acetylation. Nature (1998) 2.04
The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell (2014) 1.98
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature (2015) 1.98
Epigenetic resensitization to platinum in ovarian cancer. Cancer Res (2012) 1.88
Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. Cancer Res (1994) 1.86
Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett (2009) 1.83
Phenotypic conversion of cultured mouse embryo cells by aza pyrimidine nucleosides. Dev Biol (1978) 1.76
Reactivating the expression of methylation silenced genes in human cancer. Oncogene (2002) 1.73
A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell (2015) 1.71
The future of epigenetic therapy in solid tumours--lessons from the past. Nat Rev Clin Oncol (2013) 1.70
A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation. Science (2016) 1.64
The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anticancer Agents (2003) 1.58
Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell (2015) 1.58
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol (2015) 1.57
Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells. Proc Natl Acad Sci U S A (1999) 1.55
Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. Nature (2014) 1.47
DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res (2001) 1.45
Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget (2013) 1.44
Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia (2013) 1.44
Histone core modifications regulating nucleosome structure and dynamics. Nat Rev Mol Cell Biol (2014) 1.42
DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory. Cancer Res (2012) 1.35
A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer (2010) 1.34